Skip to content
ClinCalc Pro
Menu
Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management

Sodium Chloride 3% (Hypertonic Saline)

Brand names: NaCl 3%, HyperSal

Used in: Head Injury Hyponatraemia

Hypertonic sodium chloride 3% is a concentrated saline infusion used in critical care to treat symptomatic hyponatraemia and to reduce raised intracranial pressure.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

By raising plasma osmolality it draws water out of cells, including cerebral tissue, increasing serum sodium and reducing intracranial volume and pressure.

Prescribing in practice

  • Overly rapid correction of chronic hyponatraemia risks osmotic demyelination syndrome, so the rate of rise of serum sodium must be tightly controlled and frequently rechecked.
  • This is a hypertonic, potentially vesicant solution that is preferably given through a central line, as extravasation can cause tissue damage.
  • Use with caution in fluid overload, heart failure, and renal impairment because of the added sodium and volume load.

Monitoring

Check serum sodium and osmolality frequently during infusion to ensure the rate of correction stays within safe limits and to avoid overcorrection.

Counselling the patient

  • Explain to the team that serum sodium will be measured regularly and the infusion rate adjusted accordingly.
  • Highlight that concentrated saline should ideally run via central access and the site be watched for extravasation.
  • Note that neurological status should be monitored as part of assessing response and safety.

Evidence & guidelines

Hypertonic saline is a standard option for severe symptomatic hyponatraemia and raised intracranial pressure, with controlled correction rates supported by UK and European consensus guidance.

Reference: EASL Guidelines on Hyponatraemia; NICE NG158 (Head Injury); Neurocritical Care Society Guidelines 2023; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.